Cáncer de cabeza y cuello

  1. Navarro Expósito, F.
  2. López González, J.L.
  3. Álvarez-Mon Soto, M.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (I) Cáncer de pulmón. Cáncer de cabeza y cuello

Serie: 12

Número: 31

Páginas: 1833-1848

Tipo: Artículo

DOI: 10.1016/J.MED.2017.04.003 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Introducción Los carcinomas de cabeza y cuello constituyen un grupo heterogéneo de neoplasias localizadas en las vías aereodigestivas superiores, y representan el 5% de los cánceres diagnosticados en la edad adulta. Factores de riesgo Los principales factores de riesgo son el consumo de tabaco y alcohol, y la infección por el virus del papiloma y el virus de Epstein-Barr. Diagnóstico Alrededor de dos tercios de los tumores de cabeza y cuello se diagnostican en fase localmente avanzada (estadios III y IV). Tratamiento El tratamiento de los tumores de cabeza y cuello es complejo, debido a la variedad de subtipos, los límites anatómicos de la región, así como la importancia de conservar la función del órgano. La elección del tratamiento va a depender de la localización del tumor, la estadificación y la resecabilidad. Por tanto, el abordaje terapéutico de estos tumores debe ser multidisciplinar y de forma individualizada para cada paciente.

Referencias bibliográficas

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer statistics. CA Cancer J Clin. 2011:61-9.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Ca Cancer J Clin. 2016;66:7.
  • Spitz MR. Epidemiology and risk factors for head and neck cáncer. Semin Oncol. 1994;21:281.
  • Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012;6:S1-S24.
  • Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996; 56 (11):2488-92.
  • McGuirt WF, Greven K, Williams D 3rd, Keyes JW Jr, Watson N, Cappellari JO. KR PET scanning in head and neck oncology: a review. Head Neck. 1998; 20(3):208-15.
  • Dammann F, Horger M, Mueller-Berg M, Schlemmer H, Claussen CD, Hoffman J. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol. 2005;184(4):1326-31.
  • Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113(5):888-91.
  • Mui S, Li T, Rasgon BM, Hilsinger RL, Rumore G, Puligandla B. Efficacy and cost effectiveness of multihole fine-needle aspiration of head and neck masses. Laryngoscope. 1997;107(6):759-64.
  • Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010.
  • Vokes EE. Cáncer de cabeza y cuello. Harrison, Principios de Medicina Interna. 19ª ed. Madrid: McGraw-Hill Interamericana; 2016.
  • Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemothera-py and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.
  • Ozyigit G, Yang T, Chao KS. Intensity modulated radiation therapy for head and neck cancer. Curr Treat Options Oncol. 2004;5:3-9.
  • Duke RL, Campbell BH, Indresano AT, Eaton DJ, Marbella AM, Myers KB. Dental status and quality of life in long term head and neck cáncer survivors. Laryngoscope. 2005;115:678-83.
  • Laramore GE, Scott CB, al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23(4):705-13.
  • Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50.
  • Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937.
  • Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945.
  • Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;255:949-55.
  • Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.
  • Pointreau Y, Atean I, Fayette J, Calais G, Lefebvre JL. Induction chemotherapy in head and neck cancer: a new paradigm. Anticancer Drugs. 2011;22(7):613-20.
  • Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cacer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890-9.
  • Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-704.
  • Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17):1705-15.
  • Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A; Cortes-Funes H Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005; 23(34):8636-45.
  • Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ; Meta-analysis of chemotherapy in head and neck cancer, induction project, collaborative group taxanecisplatinfluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemothera-py in head and neck cancer group. J Clin Oncol. 2013;31(23):2854-60.
  • Induction Chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The department of Veterans Affairs Laryngeal Cancer Study Group. N Eng J Med. 1991; 324:1685.
  • LeFebvre J, Horiot J, Rolland F. Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers: EORTC protocol 24954-22950 (abstract). J Clin Oncol. 2007;25:303s.
  • Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-8.
  • Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498-506.
  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78.
  • Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck: 5 year survival data from a phase III randomised trial, and relation cetuximab-induced rash and survival. Lancet Oncol. 2010;11:-21-8.
  • Bourhis J. New approches to enhance chemotherapy in head and neck cancer. Ann Oncol. 2005;(16)Supl6:vi20-vi24.
  • Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9.
  • Vermorken JB, Mesia R, Vega-Villegas ME. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - Results of a randomized phase III (Ex-treme) study. NEJM 2008;359:1116-1127.
  • Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-22.
  • Patil V, Karpe A, Noronha V, Joshi A, Muddu V, Bhattacharjee A. Efficacy of second line erlotinib in patients postprogression of first line chemotherapy in head and neck cancers. Indian J Cancer. 2015;52(4):629-3.
  • Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(11):1864-71.
  • Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF; LUX-H&N 1 investigators. Afatinib versus methotrexate in older patients with second line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016;27(8):1585-93.
  • Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67.
  • Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. En prensa 2017.
  • Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines. Ann Oncol. 2010;21Suppl5:v184-6.
  • Keller F, PsychogiosG, Linke R, Lell M, Kuwert T, Iro H. Carcinoma of unknown prymary in the head and neck: comparasión between positron emissión tomography (PET) and (PET/TAC). Head Neck. 2011;33:1569.
  • Koch WM, Bhatti N, Williams MF, EiseleDW. Oncology rationale for bilateral tonsillectomy in head ande neck squamous cell carcinoma of un-known primary source. Otolaryngol Head Neck Surg. 2001;124:331.
  • Iganej S, Kagan R, Anderson P, Rao A, Tome M, Wang R. Metastatic squamous cell carcinoma of the neck from an known prymary: managment options and patterns of relapse. Head Neck. 2002;24:236.
  • Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS. Concurrent chemotherapy for N2 or N3 squamous cell carcinoma of the head and neck from occult primary. Ann Oncol. 2003;14:1306.
  • Sheadeh NJ, Ensley JF, Kucuk O, Black C, Yoo GH, Jacobs J. Benefit of postoperative chemoraiotherapy for patiens with unknown primary squamous cell carcinoma of the head and neck. Head Neck. 2006;28:1090.
  • Sher DJ, Balboni TA, Haddad RI, Norris CM jr, Posner MR, Wirth LJ. Efficacy and toxicity of chemoradiotherapy using intensity modulated radiotehrapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011;80:1405.
Fuente de los datos: Dialnet